Nisha Pandey

Health and Me

AstraZeneca Cancer Drug Lowers Death Risk By 42% In Advanced Stomach Cancer Trial

<span>AstraZeneca</span> is developing an experimental cancer drug <span>sonesitatug vedotin</span> that has reported a reduction in the risk of death by 42% in patients with advanced stomach and related cancers. The findings from their Phase 3 clinical trial was presented at the <span>European Society for Medical Oncology</span> (ESMO) Congress in Madrid on October 25.

The global CLARITY-Gastric01 trial compared the drug, also known as <span>sone-ve</span>, to chemotherapy selected by the physician in patients whose cancer had progressed after previous treatment. 

The findings showed that patients who received sone-ve lived a median of 10.6 months, compared to 6.4 months among those undergoing chemotherapy. 

The trial included 532 patients with advanced gastric cancer, gastroesophageal junction cancer or <a href="https://www.healthandme.com/health-news/137-cancer-drugs-to-cost-up-to-70-less-from-november-9-nppa-caps-trade-margins-article-156360416" data-type="tilCustomLink">oesophageal adenocarcinoma</a> whose tumours expressed the protein claudin 18.2 (CLDN18.2). The findings spark hope that the drug could offer another treatment option for patients whose disease has progressed despite early intervention.

Susan Galbraith, AstraZeneca's executive vice-president of oncology haematology research and development, said, “A 5-month improvement in overall survival is very clinically significant in a difficult to treat patient population,” according to <em>Reuters</em>.

<h2>How Does Sonesitatug Vedotin Work?</h2>

Also read: <a href="https://www.healthandme.com/health-wellness/womans-bleeding-abdominal-swelling-linked-to-rare-cancer-after-being-mistaken-for-perimenopause-what-is-fatwo-article-156403214" data-type="tilCustomLink">Woman’s Bleeding &amp; Abdominal Swelling Linked To Rare Cancer After Being Mistaken For Perimenopause: What Is FATWO</a>

Sonesitatug vedotin belongs to a class of treatments called antibody-drug conjugates (ADCs). These medicines combine an antibody that identifies a target on cancer cells with a drug that kills those cells, becoming a target-focused treatment.

Sone-ve targets CLDN18.2, a protein found on the surface of certain stomach and related cancer cells. The drug is designed to deliver its cancer killing properties to these cells.

The trial enrolled patients whose tumours showed CLDN18.2 expression in at least 25% of tumour cells. This limit could make the treatment relevant to a bigger group of patients than therapies that require higher levels of the protein.

Rui-Hua Xu, professor of medical oncology at Sun Yat-Sen University Cancer Center and the trial's principal investigator, said, “These are remarkable survival results for Sone-Ve in 2nd- and later-line metastatic <a href="https://www.healthandme.com/health-wellness/h-pylori-and-cancer-us-gastroenterologist-explains-how-a-common-stomach-infection-raises-risk-article-156350608" data-type="tilCustomLink">gastric cancer</a>, a disease where patients face a poor prognosis once initial therapy fails.”

He added that the treatment could be a shift in cancer care for patients whose tumours express CLDN18.2.

Also read: <a href="https://www.healthandme.com/health-news/first-human-spinal-cord-transplant-reported-in-russia-but-can-it-reverse-paralysis-article-156404310" data-type="tilCustomLink">First Human Spinal Cord Transplant Reported In Russia But Can It Reverse Paralysis?</a>

<h2>More About The Trial's Findings </h2>

Male Infertility, IVF Myths & Biological Clock | IVF Pioneer Answers

The results are promising but the drug did not meet the trial's other primary endpoint, which is survival without disease progression.

Progression-free survival measures how long patients live without their cancer worsening or dying. Median progression-free survival was 4.2 months with sone-ve and 3.8 months with chemotherapy.

Serious side effects related to the treatment occurred in 36.4% of patients receiving sone-ve, compared to 44.8% who did chemotherapy. However, side effects related to stomach were more frequent with sone-ve, affecting 11.1% of patients compared to 6.3% in the control group.

It is important to note that the findings are from a clinical trial and do not mean the drug is approved for routine use. Further regulatory review is needed before it can become a treatment option.

Furthermore, <a href="https://www.healthandme.com/health-news/amgen-astrazenecas-new-treatment-combination-cuts-advanced-lung-cancer-death-risk-by-58-in-trial-article-156400362" data-type="tilCustomLink">AstraZeneca</a> is also studying sone-ve in early treatment, where it could be used before patients have exhausted multiple therapies.

The company said the findings support investigating the drug in a bigger population of patients with CLDN18.2-positive cancers. The next phase of research will help establish its role in treatment and whether the survival benefit can be maintained when used earlier.

Health Conditions A-Z

health

astrazeneca-cancer-drug-lowers-death-risk-by-42-in-advanced-stomach-cancer-trial

astrazeneca

sone-ve

Stomach Cancer

stomach cancer sonesitatug vedotin

sonesitatug vedotin

european society for medical oncology

is-lemon-water-really-helpful-for-preventing-kidney-stones

Is Lemon Water Really Helpful for Preventing Kidney Stones?

womans-bleeding-abdominal-swelling-linked-to-rare-cancer-after-being-mistaken-for-perimenopause-what-is-fatwo

Woman’s Bleeding & Abdominal Swelling Linked To Rare Cancer After Being Mistaken For Perimenopause: What Is FATWO

Health News

8 Sit-Up Variations to Strengthen Your Core and Build Stability

Benefits Of Ayurvedic Health Supplement Ashwagandha

9 Anti-Inflammatory Breakfast Options You Should Try

5 Foods You Should Avoid For PCOS, Says Gynecologist

Love Sitting With Your Legs Crossed? Here’s You Should Avoid It

6 Daily Foods That Are Secretly Increasing Your Calories

9 Brain Boosters You Should Do Everyday

Hip Exercises That Will Keep You Flexible As You Age

9 Leg Exercises Office Workers’ Should Do At Home

Benefits of Having Herbal Tea Every Morning

9 Daily Habits That Boost Your Brain Power

Lower-Body Exercises That Are Game-Changers

How Drinking Apple Cider Vinegar Helps You

Aging Myths You Should Never Believe

Superfoods That Support Your Gut Health

What Happens To Your Body When You Eat Instant Noodles Every Day?

Health Issues Premature Babies Often Face

Exercises Office Workers Should Do For Their Heart Health

Reasons Why You Should Add Raw Turmeric To Your Diet

Benefits Of Drinking Milk At Night: Why You Should Do It

Food That Provides Vitamin B12 Naturally In Your Diet

Surprising Health Benefits Of Fenugreek Seeds

9 Superfoods You Should Eat For Your Brain Health

What Does Mental Health Support Look Like At Work?

Long Stretches You Should Do To Unwind From Your Day

Colon Cancer In Young Adults: Early Symptoms You Should Know

Health Benefits Of Eating Dry Fruits Everyday

Are You At Risk For Fried Rice Syndrome?

These Tests Reveal How Well You Are Aging

Lower-Back Exercises You Should Do After A Long-Day's Work

Children’s Diet – What Kids Need To Eat For Immunity Building

Common Diabetes Myths That Could Hurt Your Health

Love Spicy Food? Here’s How It Affects Your Health

Superfood List: Veggies And Fruits You Must Have For Immunity

Foods People With IBS Should Avoid

Exercises To Improve Digestion

Easy Work Lunches You Can Make In The Morning

Hunger Vs Craving: Difference Explained In 60 seconds

These Things Can Cause Your Heart To Age Faster

High Carb Foods That Are Actually Healthy

AstraZeneca is developing an experimental cancer drug sonesitatug vedotin that has reported a reduction in the risk of death by 42% in patients with advanced stomach and related cancers. The findings from their Phase 3 clinical trial was presented at the European Society for Medical Oncology (ESMO) Congress in Madrid on October 25.The global CLARITY-Gastric01 trial compared the drug, also known as sone-ve, to chemotherapy selected by the physician in patients whose cancer had progressed after previous treatment. The findings showed that patients who received sone-ve lived a median of 10.6 months, compared to 6.4 months among those undergoing chemotherapy. The trial included 532 patients with advanced gastric cancer, gastroesophageal junction cancer or oesophageal adenocarcinoma whose tumours expressed the protein claudin 18.2 (CLDN18.2). The findings spark hope that the drug could offer another treatment option for patients whose disease has progressed despite early intervention.Susan Galbraith, AstraZeneca's executive vice-president of oncology haematology research and development, said, “A 5-month improvement in overall survival is very clinically significant in a difficult to treat patient population,” according to Reuters.How Does Sonesitatug Vedotin Work?Also read: Woman’s Bleeding & Abdominal Swelling Linked To Rare Cancer After Being Mistaken For Perimenopause: What Is FATWOSonesitatug vedotin belongs to a class of treatments called antibody-drug conjugates (ADCs). These medicines combine an antibody that identifies a target on cancer cells with a drug that kills those cells, becoming a target-focused treatment.Sone-ve targets CLDN18.2, a protein found on the surface of certain stomach and related cancer cells. The drug is designed to deliver its cancer killing properties to these cells.The trial enrolled patients whose tumours showed CLDN18.2 expression in at least 25% of tumour cells. This limit could make the treatment relevant to a bigger group of patients than therapies that require higher levels of the protein.Rui-Hua Xu, professor of medical oncology at Sun Yat-Sen University Cancer Center and the trial's principal investigator, said, “These are remarkable survival results for Sone-Ve in 2nd- and later-line metastatic gastric cancer, a disease where patients face a poor prognosis once initial therapy fails.”He added that the treatment could be a shift in cancer care for patients whose tumours express CLDN18.2.Also read: First Human Spinal Cord Transplant Reported In Russia But Can It Reverse Paralysis?More About The Trial's Findings                The results are promising but the drug did not meet the trial's other primary endpoint, which is survival without disease progression.Progression-free survival measures how long patients live without their cancer worsening or dying. Median progression-free survival was 4.2 months with sone-ve and 3.8 months with chemotherapy.Serious side effects related to the treatment occurred in 36.4% of patients receiving sone-ve, compared to 44.8% who did chemotherapy. However, side effects related to stomach were more frequent with sone-ve, affecting 11.1% of patients compared to 6.3% in the control group.It is important to note that the findings are from a clinical trial and do not mean the drug is approved for routine use. Further regulatory review is needed before it can become a treatment option.Furthermore, AstraZeneca is also studying sone-ve in early treatment, where it could be used before patients have exhausted multiple therapies.The company said the findings support investigating the drug in a bigger population of patients with CLDN18.2-positive cancers. The next phase of research will help establish its role in treatment and whether the survival benefit can be maintained when used earlier.

astrazeneca cancer drug lowers death risk by 42% in advanced stomach cancer trial

About Us

Contact Us

Terms & Conditions

Privacy Policy

Company

Health and Me is a premium website with content written and curated to function as a handbook for all Health concerns.

AstraZeneca Cancer Drug Lowers Death Risk By 42% In Advanced Stomach Cancer Trial

First Human Spinal Cord Transplant Reported In Russia But Can It Reverse Paralysis?

From ₹6.2 Lakh To ₹15,900: Kerala Health Minister Defends Generic SMA Drug But Parents Want Safety Assurance

Amgen & AstraZeneca's New Treatment Combination Cuts Advanced Lung Cancer Death Risk By 58% In Trial

Health Conditions A-Z

AstraZeneca Cancer Drug Lowers Death Risk By 42% In Advanced Stomach Cancer Trial

Is Lemon Water Really Helpful for Preventing Kidney Stones?

Woman’s Bleeding & Abdominal Swelling Linked To Rare Cancer After Being Mistaken For Perimenopause: What Is FATWO